<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2587-7836-2025-3-9-12</article-id><article-id custom-type="edn" pub-id-type="custom">CYYCGD</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-469</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕХАНИЗМ ДЕЙСТВИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MECHANISM OF ACTION</subject></subj-group></article-categories><title-group><article-title>Оценка пролиферативной активности дипептидных миметиков 1-й, 2-й и 4-й петель мозгового нейротрофического фактора in vitro</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of proliferative activity of the dipeptide mimetics of the 1st, 2nd and 4th loops of the brain-derived neurotrophic factor in vitro</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6101-1035</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Логвинов</surname><given-names>И. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Logvinov</surname><given-names>I. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Логвинов Илья Олегович — н. с. лаборатории молекулярной фармакологии </p><p>Москва</p></bio><bio xml:lang="en"><p>Ilya O. Logvinov — Research Scientist Molecular pharmacology laboratory</p><p>Moscow</p></bio><email xlink:type="simple">logvinov_io@academpharm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4584-746X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николаев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolaev</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Николаев Сергей Владимирович — н. с. лаборатории молекулярной фармакологии </p><p>Москва</p></bio><bio xml:lang="en"><p>Sergey V. Nikolaev — Research Scientist Molecular pharmacology laboratory</p><p>Moscow</p></bio><email xlink:type="simple">nikolaev_sv@academpharm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9309-4872</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Антипова</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Antipova</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Антипова Татьяна Алексеевна — к. б. н., в. н. с. лаборатории молекулярной фармакологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Tatyana A. Antipova — PhD, Cand. Sci. (Biology), Leading researcher, Molecular pharmacology laboratory</p><p>Moscow</p></bio><email xlink:type="simple">antipova_ta@academpharm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «ФИЦ оригинальных и перспективных биомедицинских и фармацевтических технологий»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal research center for innovator and emerging biomedical and pharmaceutical technologies</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>12</month><year>2025</year></pub-date><volume>0</volume><issue>3</issue><fpage>9</fpage><lpage>12</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Логвинов И.О., Николаев С.В., Антипова Т.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Логвинов И.О., Николаев С.В., Антипова Т.А.</copyright-holder><copyright-holder xml:lang="en">Logvinov I.O., Nikolaev S.V., Antipova T.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/469">https://www.pharmacokinetica.ru/jour/article/view/469</self-uri><abstract><p>Цель настоящей работы состояла в изучении влияния димерных дипептидных миметиков 1-, 2и 4-й петель BDNF — ГСБ-214 (гептаметилендиамид бис-моносукцинил-метионил-серина), ГТС-201 (гексаметилендиамид бис-гексаноил-серил-лизина) и ГСБ-106 (гексаметилендиамид бис-моносукцинилсерил-лизина) на пролиферацию гиппокампальных клеток линии HT-22 с использованием МТТ-теста. Установлено, что миметики 1-, 2и 4-й петель BDNF после инкубации с клетками НТ-22 в течение 48 и 72 часов не влияли на их пролиферативную активность.</p></abstract><trans-abstract xml:lang="en"><p>The purpose of this work was to study the effect of dimeric dipeptide mimetics of the 1st, 2nd and 4th loops of BDNF – GSB-214 (heptamethylenediamide bis-monosuccinyl-methionyl-serine), GTS-201 (hexamethylenediamide bis-hexanoyl-seryl-lysine) and GSB-106 (hexamethylenediamide bis-monosuccinylseryl-lysine) on the proliferation of the HT-22 hippocampal cells using MTT-assay. It has been established that the mimetics of the 1st, 2nd and 4th loops of BDNF after incubation with HT-22 cells for 48 and 72 hours did not affect their proliferative activity.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>пролиферация</kwd><kwd>BDNF</kwd><kwd>димерные дипептидные миметики</kwd><kwd>ГСБ-214</kwd><kwd>ГТС-201</kwd><kwd>ГСБ-106</kwd></kwd-group><kwd-group xml:lang="en"><kwd>proliferation</kwd><kwd>BDNF</kwd><kwd>dimeric dipeptide mimetics</kwd><kwd>GSB-214</kwd><kwd>GTS-201</kwd><kwd>GSB-106</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009 Jun;5(6):311-22. doi: 10.1038/nrneurol.2009.54.</mixed-citation><mixed-citation xml:lang="en">Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009 Jun;5(6):311-22. doi: 10.1038/nrneurol.2009.54.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt HD, Duman RS. Peripheral BDNF produces antidepressantlike effects in cellular and behavioral models. Neuropsychopharmacology. 2010 Nov;35(12):2378-91. doi: 10.1038/npp.2010.114.</mixed-citation><mixed-citation xml:lang="en">Schmidt HD, Duman RS. Peripheral BDNF produces antidepressantlike effects in cellular and behavioral models. Neuropsychopharmacology. 2010 Nov;35(12):2378-91. doi: 10.1038/npp.2010.114.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010 Apr;70(5):289-97. doi: 10.1002/dneu.20758.</mixed-citation><mixed-citation xml:lang="en">Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010 Apr;70(5):289-97. doi: 10.1002/dneu.20758.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology. 1999 Apr 22;52(7):1427-33. doi: 10.1212/wnl.52.7.1427.</mixed-citation><mixed-citation xml:lang="en">A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology. 1999 Apr 22;52(7):1427-33. doi: 10.1212/wnl.52.7.1427.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Poduslo JF, Curran GL. Permeability at the blood-brain and bloodnerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996 Mar;36(2):280-6. doi: 10.1016/0169-328x(95)00250-v.</mixed-citation><mixed-citation xml:lang="en">Poduslo JF, Curran GL. Permeability at the blood-brain and bloodnerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996 Mar;36(2):280-6. doi: 10.1016/0169-328x(95)00250-v.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Гудашева Т.А., Тарасюк А.В., Помогайбо С.В., и др. Дизайн и синтез дипептидных миметиков мозгового нейротрофического фактора. Биоорганическая химия. 2012;38(3):280-290. doi: 10.1134/S1068162012030053.</mixed-citation><mixed-citation xml:lang="en">Gudasheva TA, Tarasyuk AV, Pomogaibo SV, et al. Design and synthesis of dipeptide mimetics of brain-derived neurotrophic factor. Russian Journal of Bioorganic Chemistry. 2012;38(3):280-290. (In Russ.). doi: 10.1134/S1068162012030053.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Гудашева Т.А., Тарасюк А.В., Сазонова Н.М. и др. Новый дипептидный миметик мозгового нейротрофического фактора селективно активирует сигнальный путь MAPK-Erk. Доклады Академии наук. 2017;47(1):108-112. doi: 10.7868/S0869565217250235.</mixed-citation><mixed-citation xml:lang="en">Gudasheva TA, Tarasiuk AV, Sazonova NM, et al. A novel dimeric dipeptide mimetic of the BDNF selectively activates the MAPK-Erk signaling pathway. Doklady Biochemistry and Biophysics. 2017;47(1):291-295. (In Russ.). doi: 10.7868/S0869565217250235.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003 Apr;4(4):299-309. doi: 10.1038/nrn1078.</mixed-citation><mixed-citation xml:lang="en">Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003 Apr;4(4):299-309. doi: 10.1038/nrn1078.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Davis JB, Maher P. Protein kinase C activation inhibits glutamateinduced cytotoxicity in a neuronal cell line. Brain Res. 1994 Jul 25;652(1):169-73. doi: 10.1016/0006-8993(94)90334-4.</mixed-citation><mixed-citation xml:lang="en">Davis JB, Maher P. Protein kinase C activation inhibits glutamateinduced cytotoxicity in a neuronal cell line. Brain Res. 1994 Jul 25;652(1):169-73. doi: 10.1016/0006-8993(94)90334-4</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
